Clinical Trial

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
Protocol Amendment History 2 changes
notable Trial sites expanded: 58 -> 95 locations 2026-07-21
notable Trial sites expanded: 55 -> 59 locations 2026-05-12
Trial Details
NCT Number NCT07424404
Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions Schizophrenia, Autism-Related Irritability
Enrollment 400 participants
Start Date 2026-04-07
Primary Completion 2030-03-08 (estimated)
Study Completion 2030-03-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-13